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Abstract Ovarian cancer (OVCa) stem cells are associated
with tumor growth, metastasis, and recurrence, which are
driving forces behind a majority of the OVCa-related
mortality. This subpopulation of cancer cells are charac-
terized by uncontrolled proliferation, high invasiveness,
and resistance against the current platinum-based therapy.
Thus, targeting OVCa cancer stem cells has been focused
in recent therapeutic development. Isolation and purifica-
tion of cancer stem cells are, however, challenging for the
lack of sensitive and specific markers. In this study, we
demonstrated that miR-551b was upregulated in OVCa
stem cells, by using a quantitative PCR array, correlating
with the pathological grades of this malignancy. In vitro
experiments indicated that miR-551b promoted the prolif-
eration, invasion, and chemoresistance of OVCa cells and
cancer stem cells. Further analysis suggested that miR-
551b functioned through the suppression of Foxo3 and
TRIM31, two important tumor suppressors. In support of
this, our in vivo experiments using mouse xenograft
models showed that inhibiting miR-551b significantly
increased the susceptibility of OVCa cells to cisplatin and
prolonged the survival of the host mice. In conclusion, our
study suggested miR-551b as a potential biomarker for
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OVCa stem cells and explored its functional mechanism,
providing a potential therapeutic target for future drug
development.
Keywords Ovarian cancer  Side population of cancer
cells  miR-551b  Cell proliferation  Cell invasion  Drug
resistance
Introduction
Ovarian cancer (OVCa) is the most common and one of the
most lethal gynecological malignancies in the world [1].
The overall 5-year survival rate has been merely 28–40 %
in the past few decades [2–4]. Primary OVCa, particularly
high-grade serous carcinoma that accounts for majority of
this malignancy, usually responds to the first-line platinum-
based chemotherapy, but the disease frequently recurs in a
more aggressive form and with increased chemoresistance
[1]. Although extensive studies have been performed on the
recurrence and chemoresistance of OVCa in the past few
decades [5, 6], the clinical outcome has not improved
substantially.
Cancer stem cells (CSCs) comprise of a small number of
cells with stem cell features among the highly heteroge-
neous mixture of various populations of cells in tumor.
Characteristically, they are poorly differentiated and self-
renewable as normal stem cells and are thus capable of
proliferating continuously and re-initiating tumor in vivo.
CSCs play a crucial role in maintaining tumor hetero-
geneity and promoting cancer cell growth and metastasis
[7, 8]. Moreover, they are generally less susceptible to
chemotherapeutic drugs and likely the re-initiator of the
recurrent cancer [9, 10]. Therefore, identifying this sub-
population of cells and eradicating them from patients may
provide an ideal opportunity to cure this disease. Indeed,
targeting CSCs by interrupting PML-RARa degradation
and BMP4 function in animal models has significantly
enhanced the regression of acute promyelocytic leukemia
and brain cancer [11, 12]. Ovarian cancer is believed to be
a stem cell disease. It may originate from ovarian surface
epithelium stem cells or fallopian tube epithelium [13–16].
A number of biomarkers have been recommended although
definitive and commonly accepted markers remain elusive
[17, 18]. Recently, a few studies isolated a side population
(SP) of cells based on their exclusion of Hoechst 33342
fluorescence. These cells demonstrate extensive features of
CSCs with respect to their proliferation, tumorigenicity,
migration, and chemoresistance, suggesting that they can
be ideal subjects in CSC studies [19]. Particularly in
OVCa, independent studies have shown that SP cells iso-
lated from fresh tumors and established cell lines are
enriched with tumor-initiating cells with CSC
characteristics and are highly chemoresistant [20, 21]. In
our previous study, we isolated SP cells from a primary
OVCa cell line established from OVCa patient ascites and
characterized their self-renewal, differentiation, and
tumorigenicity [22].
microRNAs refer to a group of small noncoding RNAs
which participate into the posttranscriptional gene expres-
sion control by inhibiting translation or accelerating
mRNA degradation [23]. Aberrant expression of micro-
RNAs frequently observed in multiple malignancies is
associated with tumor progression [24, 25]. A good
example of these is miR-551b, which is upregulated in lung
squamous cell carcinoma (SCCs) and prostate cancer, and
mediates tumor development and progression [26, 27].
Elevated miR-551b in OVCa enhances the resistance of
cancer cells to anoikis by upregulating STAT3 and c-KIT
[28].
Accumulating evidence suggests that microRNAs are
pivotal for the self-renewal of CSCs and cancer metastasis
and chemoresistance [29–31]; however, the underlying
mechanisms are yet to be fully understood. In this study,
we aimed to screen for microRNAs, which were abnor-
mally expressed in the SP cells of OVCa in comparison
with the non-SP cells. We identified miR-551b as one of
the most significantly elevated microRNAs in the SP cells
in comparison with the non-SP cells in OVCa. Using an
miR-551b mimic or an specific inhibitor, we explored the
roles of miR-551b in cell proliferation, invasion, and sus-
ceptibility to cisplatin and identified the downstream
effectors. In a mouse xenograft model, miR-551b was
targeted to confirm the regulatory roles of miR-551b in
OVCa progression and characterize the potentiality of
targeting miR-551b in future therapeutic development.
Materials and methods
Patient samples
Benign and malignant OVCa tissues and ascites fluids were
collected from Department of Obstetrics and Gynecology,
the First Hospital of Jilin University with written consents
from all patients. All protocols involving human specimens
were approved by the Human Ethics Committee of the First
Hospital of Jilin University. Detailed diagnostic and
pathological reports were collected for all patients, and
none of them had been previously treated with
chemotherapy.
Cell culture, isolation of SP cells, and transfection
Primary OVCa cells were isolated from the ascites of an
ovarian serous cystadenocarcinoma patient and maintained
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as previously described [22]. Briefly, primary ascitic cells
were harvested by centrifugation at 300g for 5 min, and red
blood cells removed by 19BD lysis buffer (BDBiosciences,
Franklin Lakes, NJ) on ice for 1 min, followed by centrifu-
gation at 300g for 3 min. Primary cells were cultured for
3 weeks in aDulbecco’smodified Eagle’smedium (DMEM,
Invitrogen, Carlsbad, CA) supplemented with 10 % fetal
bovine serum (FBS), and the floating cellswere collected and
re-cultured. This ascites-derived OVCa cell line was estab-
lished by continuous propagation. HEK293T cells were
grown in DMEM supplemented with 10 % FBS (Invitro-
gen). All cells were cultured at 37 C in a humidified
atmosphere with 5 % CO2 in the presence of penicillin
(100 units/ml) and streptomycin (100 units/ml). The cis-
platin–resistant cell line was established as described pre-
vious [32]. Briefly, cisplatin-sensitive SK-OV-3 and 8910
cells parental cells were exposed to gradually increasing
concentration of cisplatin (LC laboratories) from the initial
1 lM to final 60 lM over a 6-month period.
To isolate the SP cells, the primary ascites-derived
OVCa cells were trypsinized, pelleted, and re-suspended at
1.0 9 106 cells/ml in DMEM containing 2 % flow
cytometry staining buffer (BD Biosciences) and incubated
at 37 C for 10 min. The cells were then labeled with 5 lg/
ml Hoechst 33342 dye (Invitrogen) at 37 C for 80 min,
followed by counterstaining with 1 lg/ml propidium
iodide. A total of 100,000 cells were sorted on a BD Influx
system, and data were processed by BD FACSDiva soft-
ware (version 6.1.1, BD Biosciences).
Cells were transfected in an Opti-MEM medium (In-
vitrogen) with miR-551b mimic, miR-551b inhibitor,
scramble RNA (GeneCopoeia, Rockville, MD) or psi-
CHECK-2 plasmid (Promega, Madison, WI) using Lipo-
fectamine 2000 (Invitrogen), following the manufacturer’s
instructions. Cells were collected and analyzed 48 h after
transfection.
Cell proliferation assay
Cells were seeded into 96-well plates at 3000 cells/well
and cultured for 24 h. The medium was then replaced with
10 ll of cell counting kit (CCK)-8 reagent (Dojindo Lab-
oratories, Kumamoto, Japan) and 100 ll of HEPES-buf-
fered DMEM medium (Invitrogen) containing 10 % FBS.
After another 2.5 h of culture at 37 C, cell viability was
assessed by measuring the absorbance of individual wells
at 450 nm. Five replicates were performed for each group.
Colony formation assay
Capacities of cells to form colonies were determined by
two approaches. In the monolayer colony formation assay,
500 single cells were seeded into 35-mm dishes and
cultured for 10 days with medium refreshed every 3 days.
At measurement, the medium was discarded, cells were
stained with crystal violet (0.1 % in 20 % methanol) and
imaged under a SZX12 phase-contrast microscope
(Olympus, Tokyo, Japan), and colonies counted.
Soft agar colony formation assay was performed fol-
lowing a protocol used elsewhere with limited modifica-
tions. Briefly, 500 ll of 0.5 % agar (Sigma-Aldrich, St.
Louis, MO) prepared in appropriate cell culture medium
was aliquoted into 24-well plates (500 ll/well) and
allowed to solidify. On the top of this, 500 ll of cell sus-
pension at 2.66 9 102 cells/ml prepared in 0.3 % agar was
added. The cells were cultured for 3 weeks, with medium
refreshed twice a week, before the colonies larger than
75 lm in diameter or containing more than 50 cells were
counted under the microscope.
RNA isolation and qPCR
RNA from cells and tissues was isolated with a Trizol
reagent (Invitrogen) following the manufacturer’s instruc-
tions and used as templates in the synthesis of the first-
strand complementary DNA using a TaqMan microRNA
reverse transcription kit (Applied Biosystems, Foster City,
CA). qPCR was performed in triplicate using a TaqMan
universal PCR master mix (Applied Biosystems). The
thermal cycling conditions included a 10-min denaturation
at 95 C followed by 35 cycles of 15-s denaturation at
95 C, 1-min annealing at 60 C, and 45-s extension at
72 C.
Western blotting
Total proteins from cells and tissues were isolated with a
RIPA buffer (Cell Signaling Technology, Danvers, MA) in
the presence of a protease inhibitor cocktail (Thermo Sci-
entific), separated by sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE), and transferred
onto polyvinylidene fluoride (PVDF) membranes. After
blocking with 5 % bovine serum albumin for 1 h at room
temperature, the membranes were incubated overnight at
4 C with primary antibodies against Foxo3, TRIM31, and
GAPDH (Cell Signaling Technology) and then for 1 h at
room temperature with appropriate horseradish peroxidase-
conjugated secondary antibodies (Abcam, Cambridge,
UK). The signals were detected with an enhanced chemi-
luminescence detection kit (Thermo Scientific).
Construction of the plasmids and dual luciferase
reporter assay
The reverse complementary miR-551b (rcmiR-551b), the
wild-type and mutant 30-untranslated regions (UTR) of
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Foxo3 and TRIM31 were synthesized by TaKaRa
(Shanghai, China) and inserted into psiCHECK-2 or
pcDNA 3.1 vectors. The restriction enzymes and T4 DNA
ligase were purchased from New England Biolabs
(Ipswich, MA). The sequences were confirmed by Sanger
sequencing at Comate Bioscience (Changchun, China).
The dual luciferase reporter assay was performed using
HEK293T cells in 24-well plates. The cells were co-
transfected with 0.8 lg/well of plasmid and 30 nM of miR-
551b mimic or its inhibitor and incubated for 24 h. The
samples were then analyzed using a dual luciferase reporter
assay kit (Promega), and the assays were performed in
triplicate and repeated three times.
Cell cycling profiling
Cells were synchronized by serum starving for 24 h and
then transfected with miR-551b mimic, inhibitor, or the
scramble RNA. After 48 h, cells were detached, fixed in
70 % ethanol, and stained with propidium iodide before
being analyzed for cell cycle profiles by flow cytometry
using a FACSCanto II system (BD Biosciences). The
results were processed using a FlowJo data processing
software (FlowJo, Ashland, OR).
Cell invasion assay
Cell invasion was assessed by using a BioCoat Matrigel
invasion chamber (BD Biosciences). The 24-well plate was
fit with inserts, which were sealed with 8-lm membranes at
the bottom, and the inserts were pre-coatedwithMatrigel. To
examine cell invasion, cells were serum starved for 24 h and
added into the top chamber at 1 9 104 cells in 100 ll serum
freemedium,while 600 llmediumwith 1 %FBSwas added
to the bottom. After culturing for 12 h at 37 C, the medium
in the insert was decanted, and cells and Matrigel were
carefully removed with a cotton swab. Cells attached to the
outside of the insert were stained with DAPI and imaged and
counted under a microscope. Ten regions of interest (mag-
nification, 409) were counted for each group.
Mouse xenograft assay
All protocols using animals were approved by the Institu-
tional Animal Care and Use Committee of Jilin University.
Six-week-old female SCID mice (Shanghai Laboratory
Animal Centre, Shanghai, China) were inoculated subcu-
taneously with 3 9 104 SP cells premixed with Matrigel at
a 1:1 ratio. After the tumors were established for 2 weeks,
the mice were treated by intratumoral injection of 5 ll of
5 nM agomir, 20 nM antagomir, or saline twice a week for
4 weeks. In a second approach to examine the tumor
growth in peritoneal cavity, the SP cells re-suspended in
saline were injected intraperitoneally at 5 9 104 cells/
mouse, and the intraperitoneal administration of agomir or
antagomir (twice a week for 4 weeks) began after the
tumors were established.
Twenty mice were used for each group. Ten of them
were used to generate the survival curve, whereas the other
10 were killed 6 weeks after inoculation. Tumor tissues
were excised, weighed, and further used in qPCR and
Western blotting analyses.
Statistical analysis
Data are presented as mean ± standard error of the mean
(SEM), which was obtained from a minimum of three
repeats of each experiment. Data processing was performed
using a GraphPad Prism 5 software (GraphPad, La Jolla,
CA), and Student’s t test and one-way analysis of variance
(ANOVA) were used to estimate the significance of dif-
ference, and p\ 0.05 was considered significant.
Results
miR-551b is elevated in OVCa
To identify microRNAs aberrantly expressed in the OVCa
SP cells in comparison with the non-SP cells, the expres-
sion of 16 microRNAs was quantified by qPCR array
analysis performed by Shanghai Biotechnology Corpora-
tion (Shanghai, China). In the results, miR-551b was one of
the top 10 microRNAs that were upregulated in the OVCa
SP cells compared to the non-SP population. This result
was validated by a separate qPCR analysis for miR-551b
(Fig. 1a). Consistent with this, significantly higher levels of
miR-551b were detected in tissues from the advanced
serous OVCa than the early stage (Fig. 1b), suggesting the
association of miR-551b expression with OVCa progres-
sion. Furthermore, miR-551b was significantly upregulated
in the recurrent serous OVCa compared to the primary
tumors (Fig. 1c), and the cisplatin-resistant cells expressed
more miR-551b than the susceptible cells (Fig. 1d), cor-
relating with its overexpression in the stem cell-enriched
SP cells, which are believed to drive tumor recurrence.
miR-551b promotes the proliferation and invasion
of OVCa cells
The cellular roles ofmiR-551bwere characterized by in vitro
assays using the primaryOVCa cell line established in house.
Cells were transfected with miR-551b mimic, miR-551b
inhibitor, or the scramble RNA, and the changes in the
expression of miR-551b were confirmed by qPCR (Fig. 2a).
As a result, upregulating miR-551b expression led to
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significant increase in cell proliferation, while cells with
miR-551b inhibitor showed no difference from the scramble
transfected cells (Fig. 2b). Similar results were obtained in
the monolayer colony formation assay (Fig. 2c). The
enhancement of cell proliferation by miR-551b was sup-
ported by the profiling of the cell cycle. In Fig. 2d, flow
cytometry analysis demonstrated that increased miR-551b
reduced the cell population in the G1 phase while increasing
that in the S phase, suggesting that this microRNA may
promote the transition from G1 to S phase.
The invasion potential of cells transfected with miR-
551b mimic, miR-551b inhibitor, or the scramble RNA was
examined by a transwell system in which the inserts were
pre-coated with a layer of Matrigel. The results indicated a
significant increase in the number of cells migrating
through Matrigel when the primary OVCa cells were
transfected with miR-551b mimic, whereas those with
miR-551b inhibitor showed no apparent difference, com-
pared to the cells with the scramble control (Fig. 2e).
miR-551b promotes the colony formation of the SP
cells and confers them chemoresistance
To further dissect the functions of miR-551b in OVCa
cells, we sorted out the SP cells from the ascitic OVCa cell
population and performed the soft agar colony formation
assay after manipulating their miR-551b expression
(Fig. 3a). The results indicated that the SP cells transfected
with miR-551b mimic produced more colonies than the
scramble control (Fig. 3b). Consistently, SP cells trans-
fected with miR-551b mimic had a smaller G1 but a larger
S population of cells than those treated with the scramble
RNA (Fig. 3c). More importantly, in these primary CSCs,
inhibiting miR-551b expression using a sequence-specific
inhibitor (Fig. 3a) dramatically reduced the colony for-
mation capacity (Fig. 3b), and these data were correlated
with a significantly larger G1 but a smaller S population of
SP cells treated by miR-551b inhibitor (Fig. 3c).
Cancer stem cells are believed to be crucial in the
chemoresistance of cancer due to their less responsiveness
to the current platinum-based therapy [20, 33]. We thus
further characterized whether miR-551b was involved in
the chemoresistance of OVCa. The SP cells transfected
with miR-551b mimic, miR-551b inhibitor, or the scramble
RNA were exposed to a range of doses of cisplatin, and
their viability assessed after 3 days. The results demon-
strated a decreased susceptibility of cells treated with miR-
551b mimic to cisplatin and an increased responsiveness of
cells with miR-551b inhibitor (Fig. 3d). The IC50 values
for cells with the scramble RNA, miR-551b mimic, and
Fig. 1 miR-551b is upregulated in the side population of an ascites-
derived OVCa cell line, and its expression correlates with the stage,
recurrence, and chemoresistance of OVCa. a qPCR analysis indicates
a higher level of miR-551b in the side population of the ascites-
derived OVCa cell line than the non-side population, b expression of
miR-551b in ovarian serous cystadenocarcinoma tissues with varied
levels of differentiation was examined by qPCR, in comparison with
ovarian serous cystadenoma. Ten patients were included in each
group, c expression of miR-551b in the primary (Stage III) and
recurrent OVCa. Samples from 10 patients were examined in each
group. **p\ 0.01, d expression of miR-551b was compared between
the cisplatin-sensitive and cisplatin-resistant OVCa cells. **p\ 0.01
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miR-551b inhibitor were 2.33, 3.41, and 1.49 lg/ml,
respectively.
Identification of the downstream targets of miR-
551b
We next asked how miR-551b executes its important
functions in the proliferation, invasion, and chemoresis-
tance of OVCa cells. Using three microRNA target pre-
diction algorithms, including TargetScan, Pictar, and
microRNA, we found that Foxo3 and TRIM31 were among
the potential targets of miR-551b. The potential targeting
sequences are shown in Fig. 4a. Foxo3 encodes one of the
bFig. 2 miR-551b promotes the proliferation and invasion of OVCa
cell lines. a Expression of miR-551b was manipulated by transfecting
cells with miR-551b mimic or miR-551b inhibitor, using scramble
RNA as a control, and the expression of miR-551b was examined by
qPCR, b miR-551b significantly enhanced cell proliferation as
assessed by a CCK-8 assay, c monolayer colony formation of cells
transfected with miR-551b mimic or miR-551 inhibitor was compared
to the scramble control, d cell cycle profiles were determined by flow
cytometry, and the results presented as percentages of cells in G0/G1,
S, and G2/M phases, e cells with upregulated miR-551b expression
showed enhanced invasion through Matrigel in a transwell system.
Cells migrated through the Matrigel layer were stained with DAPI
and imaged under a fluorescence microscope, scale bar 100 lm.
Results are averaged from three repeats of all experiments.
**p\ 0.01; *p\ 0.05
Fig. 3 miR-551b increases the
invasion of the SP cells from the
ascites-derived OVCa cell line
and enhances their
chemoresistance. miR-551b
expression was quantified by
qPCR after the SP cells were
transfected with miR-551b
mimic, miR-551b inhibitor, or
scramble RNA control (a).
Colony formation of these cells
in soft agar was then assessed
(b), and cell cycle profiles
determined by flow cytometry
(c). The susceptibility of cells to
chemotherapeutic drug was
assessed by exposing them to
0.5–8 lg/ml cisplatin for 3 days
and measuring their viability by
a CCK-8 assay. IC50 values
were calculated using GraphPad
Prism 5.0 software. Data were
averaged from three repeats of
all experiments. *p\ 0.05
Med Oncol (2016) 33:126 Page 7 of 13 126
123
fork head family of transcription factors, which control the
expression of multiple apoptosis regulating factors, such as
p53 and p21 [34]. TRIM31 is a member of the tripartite
motif family of proteins featured by RING finger, B-box,
and coiled-coil domains. It is downregulated in multiple
malignancies, correlating with tumor stage and metastasis
[35], while its overexpression suppresses c-Src-induced
cell growth by interacting with p52 [36].
To validate the mediation of Foxo3 and TRIM31 by
miR-551b, we performed a dual luciferase reporter assay to
assess the interaction of miR-551b with the wild-type and
mutant 30-UTRs of Foxo3 and TRIM31 using the empty
psiCHECK-2 vector and rcmiR-551b as controls (Fig. 4b).
The results showed that miR-551b mimic significantly
inhibited the expression of Foxo3 and TRIM31, while miR-
551b inhibitor led to no obvious change (Fig. 4c, d). These
results were supported by qPCR and Western blotting
analyses of TRIM31 and Foxo3, respectively, using the SP
cells from OVCa (Fig. 4e). When the targeting sequences
in the 30-UTRs were mutated, the miR-551b-mediated
effects were completely abolished (Fig. 4c, d), suggesting
the interaction of miR-551b with the 30-UTRs of Foxo3 and
TRIM31.
To define whether Foxo3 and TRIM31 are involved in
the miR-551b-mediated cellular functions, Foxo3 or
TRIM31 was overexpressed in OVCa cells in the presence
or absence of miR-551b mimic (Supplemental Fig. 1A).
Cell proliferation assay demonstrated that miR-551b sig-
nificantly promoted, consistently with our data in Fig. 2b,
while exogenous Foxo3 and TRIM31 inhibited cell pro-
liferation (Supplemental Fig. 1B, C). Importantly, both
Foxo3 and TRIM31 apparently abrogated the induction of
proliferation by miR-551b when either was co-transfected
with miR-551b (Supplemental Fig. 1B, C). Flow cytometry
analysis showed that the cells were arrested at G0/G1 phase
when Foxo3 or TRIM31 was overexpressed (Supplemental
Fig. 1D). The two proteins counteracted against miR-551b
and negated the increase in S phase cells population caused
by this microRNA (Supplemental Fig. 1D). Moreover,
exogenously expressed Foxo3 or TRIM31 also overturned
the increase in cell invasion induced by miR-551b (Sup-
plemental Fig. 1E). These data suggested that miR-551b
regulates the proliferation and invasion of the OVCa SP
cells through its inhibitive effect on the expression of
Foxo3 and TRIM31.
Targeting miR-551b increases the susceptibility
of mouse xenografts to cisplatin
Mouse xenograftmodelwas employed to confirmour in vitro
observations, which suggested key roles of miR-551b in the
proliferation and invasion of OVCa cells. The SP cells were
inoculated subcutaneously into the flanks of SCIDmice, and
the established tumors were treated by intratumoral injection
of agomir or antagomir of miR-551b to up- or downregulate
miR-551b levels. At harvest after 4 weeks of treatment,
miR-551b agomir increased the tumor burden by 42 %,
compared to the controls which were injected with saline,
while miR-551b antagomir decreased the tumor burden by
38 % (Fig. 5a). Corresponding to this, mice treated with
miR-551b agomir survived for a shorter period than the
control, while the treatment with miR-551b antagomir pro-
longed the survival (Fig. 5b).
In support of the mediation of Foxo3 and TRIM31 by
miR-551b observed in vitro, Western blotting analysis
revealed that the expression of Foxo3 and TRIM31 was
inhibited in tumors treated by miR-551b agomir and
enhanced in those by miR-551b antagomir (Fig. 5c). The
data suggested that the mediation of Foxo3 and TRIM31 by
miR-551b was occurring in vivo and might play a key role
in the observed impacts of miR-551b on tumor growth
(Fig. 5a).
Our in vitro data in Fig. 3d suggested that miR-551b
mediated the resistance of the SP cells against cisplatin.
We therefore tested whether this conclusion stands in an
in vivo model. The freshly isolated SP cells were injected
intraperitoneally into SCID mice and allowed to form
tumors. Mice were treated by intraperitoneal administration
of miR-551b agomir, miR-551b antagomir, or saline,
together with 25 mg/kg cisplatin. When the mice were
killed after 4 weeks of treatment, higher tumor burdens
were measured in mice co-injected with miR-551b agomir
and cisplatin than those with saline and cisplatin (Fig. 5d).
On the other hand, mice co-administrated with miR-551b
antagomir and cisplatin grew significantly fewer tumors
(Fig. 5d), and as a result, these mice survived much longer
periods than the other two treatment groups (Fig. 5e).
Discussion
In this study, we screened for microRNAs aberrantly
expressed in the SP cells isolated from an ascites-derived
OVCa cell line in comparison with the non-SP cancer cells.
miR-551b was identified as one of the top 10 upregulated
microRNAs in the SP cells. Further in vitro and in vivo
assays suggested that miR-551b mediated the proliferation,
invasion, and chemoresistance, likely through its control
over the expression of Foxo3 and TRIM31.
Majority of the experiments in the study were performed
using the SP cells originated from malignant OVCa ascites,
which is associated with the transcoelomic metastases of
OVCa cells [37, 38]. The SP populations of cells in many
cancers demonstrate stem cell features although contra-
dictive results have also been reported for certain types of
cancer. The enrichment of CSCs in the SP population of
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OVCa cells has been confirmed by independent studies
including ours [22, 39, 40]. The results from these studies
establish that the SP cells of OVCa possess significant stem
cell characteristics, such as cell differentiation, colony
formation, tumorigenesis, and chemoresistance [22].
Therefore, the SP cells of OVCa can be a useful model in
the development of therapeutic approaches targeting CSCs
or cells with stem cell features, which are disputably the
major reasons behind the progression and the acquired
chemoresistance of many malignancies [41].
Fig. 4 Foxo3 and TRIM31 are downstream targets of miR-551b.
a Sequences of miR-551b, rcmiR-551b, and the potential targeting
regions in the 30 UTRs of Foxo3 and TRIM31 are shown. In the
mutant forms of Foxo3 and TRIM31, mutated nucleotides are
underlined, b–d association of miR-551b with rcmiR-551b, and the
wild-type and mutant forms of 30 UTRs of Foxo3 and TRIM31 in
HEK293T cells were determined by a reporter assay. Data were
averaged from three repeated experiments, e the mediation of Foxo3
and TRIM31 by miR-551b was confirmed by qPCR and Western
blotting, respectively. **p\ 0.01; *p\ 0.05
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Fig. 5 Blocking the expression of miR-551b inhibits the growth of
ovarian tumors in vivo. In the subcutaneous mouse xenograft models,
the tumor burden in mice was significantly increased by the 4-week
treatment of miR-551 agomir, but reduced by miR-551b antagomir
(a), and correlated with these, mice injected with miR-551b agomir
had poorer survival (p = 0.0035), while those with miR-551b
antagomir showed better survival in comparison with the control
mice (b). Expression of miR-551b, Foxo3 and TRIM31 in the
xenografts was assessed by qPCR and Western blotting (c). In the
intraperitoneal mouse xenograft model, mice were injected intraperi-
toneally with SP cells and were treated for 4 weeks with miR-551b
agomir, miR-551b antagomir, or the vehicle, in the presence of
25 mg/kg cisplatin (intraperitoneal delivery). Tumor burdens in mice
at harvest were compared (d), and survival curves graphed (e).
**p\ 0.01; *p\ 0.05
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Emerging evidence suggests a critical role of micro-
RNAs in OVCa progression. Upregulation of the miR-200
family microRNAs predicts poor progression-free and
overall survivals of OVCa patients [42]. On the other hand,
microRNAs can be tumor suppressive. miR-7 reverses
epithelial–mesenchymal transition by inactivating AKT/
ERK1/2 via EGFR and inhibits OVCa metastasis [43].
miR-9 inhibits the proliferation, migration, and invasion of
serous OVCa cells by blocking TLN1-mediated FAK/AKT
pathway [44]. In addition, expression of miR-496, miR-
152, miR-422b, and miR17-3p correlates with acquired
cisplatin resistance [45]. The current study demonstrates
that miR-551b is over 100-fold higher in the SP cells than
in the non-SP population of cells, implicating that this
microRNA is required to maintain the phenotypic features
of the SP cells. Indeed, miR-551b upregulates STAT3 and
c-KIT and enhances the resistance of ovarian tumor cells to
anoikis [28]. This mechanism may extend to other
anchorage-free settings since miR-551b expression is also
enhanced in the circulating prostate cancer cells [27].
Further studies are needed to define whether miR-551b is
involved in other processes important for OVCa metas-
tases, such as spheroid formation and the colonization of
OVCa cells on the surfaces of adjacent organs in the
peritoneal cavity [27, 46].
In solid ovarian tumors, miR-551b expression correlates
with tumor grades (Fig. 1b), suggesting its close associa-
tion with cancer progression. This is consistent with the
association of miR-551b expression with the survival of
296 OVCa patients, as demonstrated by previous micro-
RNA profiling [47]. In addition, miR-551b expression is
elevated in the recurrent OVCa compared to the primary
disease (Fig. 1c) although its functional importance in
OVCa recurrence is unknown. In lung cancer cells, miR-
551b inhibits the expression of catalase and enhances the
accumulation of reactive oxygen species and the expres-
sion of mucin-1, contributing to the acquired resistance to
apoptosis and chemotherapy [48].
Our data support significant roles of miR-551b in the
proliferation and invasion of the ascitic SP cells in vitro
and the growth of tumor xenografts in mice (Fig. 5). This is
likely through the suppression of Foxo3 and TRIM31
expression as shown by the binding of miR-551b to the
UTRs of Foxo3 and TRIM31 transcripts (Fig. 4) and the
reversing of the miR-551 mimic-induced phenotype by
exogenous Foxo3 and TRIM31 (Supplemental Fig. 1).
Foxo3 is a known regulator of p53 and p21 [34], exhibiting
a tumor-suppressive role in high-grade pelvic serous car-
cinogenesis [49]. The observed shifts of the SP cells
between G1 and S phases of the cell cycle in response to
the manipulation of miR-551b expression are consistent
with the known functions of Foxo3 in cell cycle progres-
sion [34]. TRIM31 is aberrantly expressed in multiple
cancers. It is downregulated in lung cancer with tumor
stage [35], whereas its elevation in gastric carcinoma leads
to inhibition of cell proliferation [50]. At molecular level,
TRIM31 interacts with p52 and regulates Src kinase [50].
Our results suggest a tumor-suppressive role of TRIM31 in
OVCa cells in response to miR-551b. Consistent with our
in vitro observations, inhibitions of Foxo3 and TRIM31 by
miR-551b were observed in mouse xenografts (Fig. 5),
suggesting the occurrence of the signaling in vivo.
In summary, our results demonstrate that miR-551b is
significantly higher in OVCa SP cells than the non-SP
cells. Its upregulation correlates with increased prolifera-
tion and invasion of the SP cells in vitro and growth of the
mouse xenografts in vivo. Moreover, our data also suggest
that miR-551b contributes to the development of
chemoresistance of the SP cells in vitro and in vivo, and its
inhibition sensitizes cancer cells to chemotherapy,
emphasizing its value in future therapeutic development. In
an attempt to explore the mechanism of miR-551b func-
tioning, we have shown that miR-551b functions through
Foxo3 and TRIM31. However, further studies are required
to define the mechanism that triggers its elevation in cancer
and the network through which this microRNA relays its
signals in its pro-cancerous functions.
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